Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 2/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.34 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.33 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13025813 | 0.87 | PDE4D (0.38) | VEGFAPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13066967 | 0.85 | VEGFA (0.36) | VEGFAPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13025994 | 0.85 | VEGFA (0.35) | VEGFAPDE4DPDE4APDE4BFFAR4 | |
| SCHEMBL13025726 | 0.84 | FFAR4 (0.41) | VEGFAS1PR1FFAR4S1PR3 | |
| SCHEMBL13025951 | 0.83 | FFAR4 (0.40) | VEGFAS1PR1FFAR4S1PR3 | |
| SCHEMBL13025732 | 0.82 | VEGFA (0.39) | VEGFAPDE4DPDE4APDE4BPDE4C | |
| SCHEMBL13025958 | 0.81 | FFAR4 (0.39) | VEGFAS1PR1FFAR4S1PR3 | |
| SCHEMBL13025735 | 0.81 | FFAR4 (0.37) | VEGFAS1PR1FFAR4S1PR3 | |
| SCHEMBL1510004 | 0.80 | CYP2C9 (0.39) | VEGFAAPPFFAR4 | |
| SCHEMBL13025632 | 0.79 | VEGFA (0.41) | VEGFAPDE4DPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | VEGFA 1939/4885EP300 2550/4885IKBKE 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.